@article {4308,
	title = {Clinical case conference: unobserved "home" induction onto buprenorphine.},
	journal = {Journal of addiction medicine},
	volume = {8},
	year = {2014},
	month = {2014 Sep-Oct},
	pages = {309-14},
	abstract = {Unobserved or "home" buprenorphine induction has become a common clinical practice. Patients take the initial and subsequent doses of buprenorphine after, rather than during, an office visit. This clinical case summarizes an unobserved induction onto buprenorphine in a typical new patient. We review the core issues surrounding patient selection, feasibility, logistics, safety, and effectiveness of unobserved buprenorphine induction. Prescribers, treatment providers, policy makers, and patients should weigh the benefits of observed induction (maximum clinical supervision) with the reduced resource burden, flexibility, and comparable safety of unobserved induction.},
	issn = {1935-3227},
	doi = {10.1097/ADM.0000000000000060},
	author = {Lee, Joshua D and McNeely, Jennifer and Grossman, Ellie and Vocci, Frank and Fiellin, David A}
}
